Search Results for “immune” – Page 67 – media

Direct Acting Antiviral Drugs For The Treatment Of Hepatitis C

This is fourth installment in my series on progress toward the elimination of Hepatitis C infection and disease. Read more about Hepatitis C in part one, part two and part three. Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A … [+] In the previous articles of this series, I’ve outlined the seriousness and uncontrolled nature of hepatitis C. In the absence of a vaccine, the control and treatment of hepatitis C, much like that of HIV/AIDS, depends on the use of antiviral medications. Recent progress in the development of several highly active, anti-hepatitis C drugs has been a triumph of modern medicine. These drugs usher in an era of effective treatment and even elimination of hepatitis C both nationally and globally. Later in this series I will describe how these drugs have been used to eliminate hepatitis C from some countries and discuss how that success may be ...
- Source: drugdu
- 264
- April 4, 2023
mRNA vaccine beats infection for key defense against COVID-19, Stanford Medicine scientists find

Stanford Medicine researchers have shown that prior SARS-CoV-2 infection reduces killer T cells’ response to vaccination. These cells are crucial for eliminating the virus from the body. March 28, 2023 – By Bruce Goldman T cells are more difficult to measure than antibodies, but they play a crucial role in fighting pathogens.Kateryna Kon/Shutterstock.com The Pfizer/BioNTech mRNA vaccine directed at COVID-19 is much better than natural infection at revving up key immune cells called killer T cells to fight future infection by SARS-CoV-2, the virus that causes COVID-19, Stanford Medicine investigators have found. The scientists also showed, in a study published online in Immunity, that getting infected by SARS-CoV-2 before getting vaccinated lowers the vaccine’s otherwise exceptional ability to spur proliferation and activation of killer T cells directed at SARS-CoV-2. Their finding suggests that those hoping to avoid the manifold health risks associated with COVID-19 would do well to get vaccinated before they contract ...
- Source: drugdu
- 144
- March 31, 2023
Is Parkinson’s disease, ‘world’s fastest growing brain disease,’ mostly preventable?

Researchers warn that a colorless chemical known as trichloroethylene (TCE) — which has been used to dry-clean clothes, degrease metals and decaffeinate coffee — may be linked to the dramatic increase in Parkinson’s disease (PD) cases. They recently published a series of seven cases in the Journal of Parkinson’s disease that illustrate TCE’s harmful health effects and the potential PD association. “TCE is associated with a 500% increased risk of Parkinson’s disease,” lead author Dr. Ray Dorsey, professor of neurology at the University of Rochester in New York and author of “Ending Parkinson’s Disease,” told Fox News Digital. The chemical reproduces the features of the neurological disease in laboratory animals. It impairs the function of the energy-producing parts of cells called mitochondria, which are known to be damaged in Parkinson’s disease, Dorsey added. Widespread applications of TCE TCE was first synthesized in the lab in ...
- Source: drugdu
- 153
- March 30, 2023
Vaccination, Paxlovid decrease risk of long Covid, studies show

People who are vaccinated or who take Paxlovid during a Covid-19 infection have a lower risk of developing long Covid, new research shows. The US Centers for Disease Control and Prevention defines long Covid as new, returning or ongoing health issues more than four weeks after an initial infection. According to the CDC, 1 in 5 Covid-19 survivors ages 18 to 64 and 1 in 4 survivors 65 or older have an ongoing health issue that might be attributable to Covid-19 infection。 A study published Thursday in JAMA Internal Medicine analyzed data from 41 studies, including more 860,000 people around the world. Of the four studies with vaccination information of nearly 250,000 people, those who had been vaccinated against Covid-19 had almost half the risk of long Covid than people who weren’t vaccinated. “These findings are important because they enable us to better understand who may develop ...
- Source: drugdu
- 130
- March 30, 2023
GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate There are currently no licensed vaccines offering simultaneous protection against all five serogroups

GSK has reported positive top-line results from a phase 3 study of its five-in-one meningococcal vaccine candidate, MenABCWY, in healthy individuals aged ten to 25 years. Invasive meningococcal disease (IMD) is an uncommon but serious illness that can cause life-threatening complications or even death, with the highest incidence occurring in children and adolescents. Five Neisseria meningitides serogroups – A, B, C, W, and Y – account for nearly all IMD cases, but there are currently no licensed vaccines that offer simultaneous protection against all of them. In the US, two separate vaccines needing four injections are required to protect against all five serogroups. This regimen, together with low awareness of the disease, can lead to poor immunisation rates, with an estimated coverage of only 31% of adolescents in the US. It is hoped that GSK’s MenABCWY, which combines the antigenic components of its licensed Bexsero (MenB) and Menveo (MenACWY) meningococcal ...
- Source: drugdu
- 156
- March 27, 2023
Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon

On March 21, Selecta Biosciences and Sobi announced positive pivotal results from two phase III studies (DISSOLVE I and DISSOLVE II). These two placebo-controlled, randomized clinical trials were designed to evaluate the safety and efficacy of two different dose levels of SEL-212 in adult patients with chronic refractory gout. Gout is an autoinflammatory disease in which patients experience severe pain and debilitating inflammatory arthritis due to deposits of pro-inflammatory sodium urate (MSU) crystals. Patients with chronic refractory gout often have a high tissue MSU burden, which can lead to frequent gout attacks and chronic arthritis. Gout is the most common inflammatory arthritic disease in the United States. SEL-212 has the potential to reduce serum uric acid and MSU deposition in patients with chronic refractory gout. Recombinant uricase is highly immunogenic in the human body. Through Selecta’s proprietary ImmTOR platform, SEL-212 has the potential to alleviate the formation of anti-drug antibodies, ...
- Source: drugdu
- 157
- March 24, 2023
Sanofi Reports Strong Quarterly Earnings, Driven by Success of Key Products

Sanofi, the French multinational pharmaceutical company, has reported strong quarterly earnings for the fourth quarter of 2022, driven by the success of several key products. The company’s performance beat analysts’ profit forecast, and shares rose in response to the news. Sanofi’s revenue for the quarter was €10.2 billion, up 6.7% from the same period the previous year. Net income was €1.3 billion, an increase of 28.6% compared to the same quarter in 2021. The strong results were driven by the success of several of the company’s products, including Dupixent, Aubagio, and Lantus. Dupixent, a treatment for atopic dermatitis and asthma, was a particular standout, with sales of €1.3 billion in the quarter, up 42.9% from the same period in 2021. The drug has been a major growth driver for Sanofi, with sales expected to reach €10 billion by 2025. Aubagio, a treatment for multiple sclerosis, also performed ...
- Source: drugdu
- 123
- March 24, 2023
New Drug Combination Shows Promise in Treating Lung Cancer

Researchers from the University of Texas MD Anderson Cancer Center have found that a combination of two drugs may be effective in treating non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer and accounts for approximately 85% of all lung cancer cases. The study, published in the journal Nature Medicine, involved analyzing data from over 1,000 patients with NSCLC. The researchers identified a group of genes that were associated with resistance to immunotherapy, a type of cancer treatment that uses the body’s immune system to fight cancer cells. The researchers then tested a combination of two drugs, a checkpoint inhibitor and a targeted therapy, in mouse models of NSCLC. The checkpoint inhibitor works by releasing the brakes on the immune system, allowing it to attack cancer cells. The targeted therapy works by inhibiting a protein that is overexpressed in many types of cancer ...
- Source: drugdu
- 125
- March 21, 2023
Big news! Hengrui ADC innovative drug SHR-A1811 new indication to be included in breakthrough therapy species

Recently, Hengrui Medicine’s ADC innovative drug SHR-A1811 for the treatment of HER2-mutated advanced non-small cell lung cancer who failed previous platinum-based chemotherapy was proposed to be included in the public list of breakthrough therapy varieties by the Center for Drug Evaluation of the National Medical Products Administration. The study was led by Professor Lu Shun from the Chest Hospital Affiliated to Shanghai Jiaotong University, and a total of 10 centers across the country participated. At the same time, the other two indications of SHR-A1811 have been included in the list of breakthrough therapy varieties by the Drug Evaluation Center of the State Drug Administration in February this year. The indications are: low expression of human epidermal growth factor receptor 2 (HER2). Recurrent or metastatic breast cancer and human epidermal growth factor receptor 2 (HER2) positive recurrent or metastatic breast cancer. Lung cancer is currently the leading cause of cancer-related death ...
- Source: drugdu
- 142
- March 20, 2023
New Study Shows Potential for Personalized Treatment for Lung Cancer

Lung cancer is a leading cause of cancer-related death worldwide, and treatment options are limited for patients with advanced disease. However, a recent study published in the journal Nature has shown promising results for a new approach to treating lung cancer using personalized medicine. The researchers analyzed the genomes of more than 2,000 patients with non-small cell lung cancer and identified several genetic mutations that were associated with a better response to immunotherapy, a type of cancer treatment that helps the immune system fight cancer. The researchers also developed a personalized treatment algorithm that took into account the genetic mutations of each patient’s tumor. They found that patients who received personalized treatment based on their tumor’s genetic profile had a better response to immunotherapy than those who received standard treatment. The lead author of the study, Dr. Trever Bivona, said that the results were “very promising” and showed that personalized ...
- Source: drugdu
- 162
- March 20, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.